PL1804804T3 - Kwas 3-[4-dibenzo[b,f][1,4]oksazepin-11-ylo)piperazyn-1-ylo]-2,2-dimetylopropionowy do zastosowania w leczeniu zaburzeń snu - Google Patents

Kwas 3-[4-dibenzo[b,f][1,4]oksazepin-11-ylo)piperazyn-1-ylo]-2,2-dimetylopropionowy do zastosowania w leczeniu zaburzeń snu

Info

Publication number
PL1804804T3
PL1804804T3 PL05801120T PL05801120T PL1804804T3 PL 1804804 T3 PL1804804 T3 PL 1804804T3 PL 05801120 T PL05801120 T PL 05801120T PL 05801120 T PL05801120 T PL 05801120T PL 1804804 T3 PL1804804 T3 PL 1804804T3
Authority
PL
Poland
Prior art keywords
oxazepin
dibenzo
piperazin
treatment
propanoic acid
Prior art date
Application number
PL05801120T
Other languages
English (en)
Polish (pl)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of PL1804804T3 publication Critical patent/PL1804804T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20[b, f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL05801120T 2004-09-21 2005-09-21 Kwas 3-[4-dibenzo[b,f][1,4]oksazepin-11-ylo)piperazyn-1-ylo]-2,2-dimetylopropionowy do zastosowania w leczeniu zaburzeń snu PL1804804T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19
EP05801120A EP1804804B1 (en) 2004-09-21 2005-09-21 3-[4-(DIBENZO[b,f][1,4]OXAZEPIN-11-YL)-PIPERAZIN-1-YL]-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS
PCT/US2005/034015 WO2006034414A2 (en) 2004-09-21 2005-09-21 Loxapine analogs and methods of use thereof

Publications (1)

Publication Number Publication Date
PL1804804T3 true PL1804804T3 (pl) 2012-08-31

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05801120T PL1804804T3 (pl) 2004-09-21 2005-09-21 Kwas 3-[4-dibenzo[b,f][1,4]oksazepin-11-ylo)piperazyn-1-ylo]-2,2-dimetylopropionowy do zastosowania w leczeniu zaburzeń snu

Country Status (19)

Country Link
US (3) US7592333B2 (enExample)
EP (1) EP1804804B1 (enExample)
JP (1) JP5049129B2 (enExample)
KR (1) KR101264444B1 (enExample)
AT (1) ATE542536T1 (enExample)
AU (1) AU2005286713B2 (enExample)
BR (1) BRPI0515518A (enExample)
CA (1) CA2580250C (enExample)
CY (1) CY1112590T1 (enExample)
DK (1) DK1804804T3 (enExample)
EA (1) EA012610B1 (enExample)
ES (1) ES2378452T3 (enExample)
MA (1) MA28985B1 (enExample)
MX (1) MX2007003032A (enExample)
NO (1) NO20071604L (enExample)
NZ (1) NZ553900A (enExample)
PL (1) PL1804804T3 (enExample)
PT (1) PT1804804E (enExample)
WO (1) WO2006034414A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
MXPA05007784A (es) * 2003-01-23 2005-09-30 Acadia Pharm Inc Empleo de la n-desmetilclozapina para tratar las enfermedades neuropsiquiatricas humanas.
PT1696931E (pt) * 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
MXPA06011320A (es) * 2004-04-01 2007-03-21 Acadia Pharm Inc Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
WO2006049734A2 (en) * 2004-10-29 2006-05-11 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
RU2459811C2 (ru) * 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
BRPI0808828A8 (pt) * 2007-03-15 2017-11-28 Aryx Therapeutics Inc Compostos de dibenzo[b,f][1,4]oxazapina
US8827979B2 (en) 2007-03-19 2014-09-09 Insuline Medical Ltd. Drug delivery device
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2231229A1 (en) 2007-12-18 2010-09-29 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
CN102245137A (zh) 2008-11-07 2011-11-16 茵苏莱恩医药有限公司 用于药物递送的装置和方法
WO2014116684A1 (en) * 2013-01-22 2014-07-31 Edward Roberts Non-peptidic neuropeptide y receptor modulators
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
AU2020370063B2 (en) * 2019-10-21 2025-10-23 Alairion, Inc. 3-(4-(11H-dibenzo[b,e][1,4]azepin-6-yl)piperazin-1-yl)- and 3-(4-(dibenzo[b,f][1,4]oxazepin/thiazepin/diazepin-11-yl)piperazin-1-yl)-propanoic acid derivatives as H1 and 5-HT2A-receptor modulators for the treatment of sleep disorders
WO2025076527A1 (en) * 2023-10-07 2025-04-10 Inspire Medical Systems, Inc. Pulmonary therapy for sleep disordered breathing care

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (enExample) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
WO1998036738A1 (en) 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) * 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20050049146A1 (en) 2001-11-05 2005-03-03 Chiarello John F. Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
EP1578198A1 (en) 2002-12-20 2005-09-28 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
MX2007003032A (es) 2007-05-21
MA28985B1 (fr) 2007-11-01
US7592333B2 (en) 2009-09-22
NZ553900A (en) 2010-10-29
EP1804804B1 (en) 2012-01-25
WO2006034414A2 (en) 2006-03-30
EA200700702A1 (ru) 2007-10-26
PT1804804E (pt) 2012-03-30
US20090186872A1 (en) 2009-07-23
WO2006034414A3 (en) 2006-09-08
CY1112590T1 (el) 2016-02-10
JP5049129B2 (ja) 2012-10-17
NO20071604L (no) 2007-06-20
EA012610B1 (ru) 2009-10-30
AU2005286713A1 (en) 2006-03-30
EP1804804A2 (en) 2007-07-11
AU2005286713B2 (en) 2010-10-28
CA2580250A1 (en) 2006-03-30
DK1804804T3 (da) 2012-02-20
KR101264444B1 (ko) 2013-05-20
EP1804804A4 (en) 2010-11-24
CA2580250C (en) 2013-05-14
US20060063928A1 (en) 2006-03-23
ES2378452T3 (es) 2012-04-12
US8101596B2 (en) 2012-01-24
US20060063755A1 (en) 2006-03-23
KR20070060126A (ko) 2007-06-12
BRPI0515518A (pt) 2008-07-29
ATE542536T1 (de) 2012-02-15
JP2008513510A (ja) 2008-05-01

Similar Documents

Publication Publication Date Title
PL1804804T3 (pl) Kwas 3-[4-dibenzo[b,f][1,4]oksazepin-11-ylo)piperazyn-1-ylo]-2,2-dimetylopropionowy do zastosowania w leczeniu zaburzeń snu
MY144727A (en) Consumer products for enhancing mental focus
GB0228410D0 (en) Novel Compounds
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
TW200607451A (en) Azinylimidazoazines and azinylcarboxamides
TN2010000237A1 (en) Novel compounds and compositions and methods of use
SI1723144T1 (sl) Dodatne heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnega glutamatnega receptorja
MY150448A (en) 1- [2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition
WO2003103575A3 (en) Compounds, compositions, and methods
WO2005113590A3 (en) Bmp10 propeptides and related methods
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
PL1877390T3 (pl) Związki benzizoksazolopiperazynowe i sposoby ich stosowania
DE50304868D1 (de) Verwendung von mandelsäurealkylamiden als aromastoffe
IL176111A0 (en) 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri
WO2006120481A3 (en) 2,3-substituted fused bicyclic pyrimidin-4(3h)-ones which modulate the function of the vanilloid-1 receptor (vr1)
SI1789398T1 (sl) 2-amino-kinazolinski derivati, uporabni kot inhibitorji b-sekretaze (bace)
GB0328900D0 (en) Novel compounds
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
HUE050758T2 (hu) Glutamátmoduláló szerek mentális rendellenességek kezelésére
TR200200278T2 (tr) Kalsilitik bileşimler
JO2747B1 (en) Vehicles
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
WO2006135694A3 (en) Uii-modulating compounds and their use
SI1804804T1 (sl) 3-(4-(DIBENZO(b,f)(1,4)OKSAZEPIN-11-IL)PIPERAZIN-1-IL)2,2-DIMETIL PROPANOJSKA KISLINA ZA UPORABO PRI ZDRAVLJENJU MOTENJ SPANJA